According to data from the NPF Parkinson's Outcomes Project thus far, there is currently wide variability in the use of different medicines and treatment plans in Parkinson's disease. In planning for patient care, physicians typically rely on clinical evaluation, a patient's self-reporting of symptoms[i] and response to medication to guide therapy, potentially increasing the risk of inconsistent and diverse outcomes. "Some Parkinson's patients are thriving, while others are not. Our goal is to determine what makes that difference. By including the PKG™ System as an element of routine care, this study will enable us to consider the interplay of continuous objective measures of patient mobility among the other factors that ultimately produce different results in different people, and likely paths toward better outcomes. Our goal is not only to optimize today's care of Parkinson's patients, but also to help guide tomorrow's," said Dr. Schmidt.
"The PKG™ System was FDA cleared in the U.S. in 2014, and many leading clinicians now have extensive experience with this technology, making this an ideal time to initiate this important clinical study," Professor Horne said. "This is one of several post-marketing studies currently underway with the PKG™ that will provide a wealth of new data highlighting the role that objective assessment of symptoms can play in improving patient care in Parkinson's disease in the years ahead."
Ad Statistics
Times Displayed: 49670
Times Visited: 1409 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
About Parkinson's Disease
Parkinson's disease (PD) is a chronic, progressive movement disorder that affects the lives of at least one-half million patients in the United States[ii]. The main motor (or movement) related symptoms of Parkinson's disease are bradykinesia (slowness of movement), rigidity, tremors and postural instability. [iii] Other non-movement symptoms include speech and swallowing difficulties, cognitive impairment, depression or other emotional changes. As the disease progresses, symptoms may interfere with daily activities. Parkinson's disease can be difficult to diagnose and currently there is no cure. [iv] However, a variety of medications and surgery can help ease the symptoms for some patients.[v]
About the National Parkinson Foundation (NPF)
Founded in 1957, the National Parkinson Foundation's mission is to make life better for people with Parkinson's through expert care and research. NPF has funded more than $189 million in care, research and support services. For more information, visit www.parkinson.org, or call the NPF Helpline at 1-800-4PD-INFO (473-4636).
About Global Kinetics Corporation
Global Kinetics Corporation is committed to improving the lives of those with Parkinson's disease and other movement disorders with advanced medical technologies. The company was formed in 2007 to commercialize its lead product, the Personal KinetiGraph™ (PKG™). Developed by neurologists at the world-renowned Florey Institute of Neuroscience & Mental Health in Melbourne, Australia, the Personal KinetiGraph™ enables the precise monitoring, quantification and reporting of movement symptoms of neurological diseases. Global Kinetics Corporation, a privately held company, is headquartered in Melbourne, Australia. For more information visit: www.globalkineticscorporation.com.
Back to HCB News
